Market Trends of Recombinant Protein Industry
Antibody Segment is Expected to Witness a Significant Growth Over the Forecast Period.
The recombinant antibody production procedure involves cloning antibody gene libraries into phage vectors and allowing the phages to infect a host cell line. The host cells then produce daughter phages expressing the recombinant antibodies on their surfaces. The genes can be inserted into a recombinant protein expression system, and the antibodies can be produced in large quantities after a process of selection for antibodies with the desired characteristics, impacting the recombinant protein expression system market.
The rising cases of diabetes and the increasing use of antibodies are driving the growth of this segment. For instance, in 2021, the International Diabetes Federation (IDF) reported that globally in the year 2021, 537 million cases of diabetes were reported and that this number is expected to increase to 783 million by 2045. So, the growth of the segment is being driven by the rise of chronic diseases like diabetes, which is increasing the demand for recombinant antibodies and therapeutic proteins in the protein-based therapeutics market.
The mergers, acquisitions, partnerships, and new product launches by key market players are also driving the growth of this segment. For example, in February 2021, Sanofi and GSK started a new phase 2b study with 720 adults over the age of 18 to find the best antigen dose for phase 3 testing of the adjuvanted recombinant protein COVID-19 vaccine candidate, contributing to the growth of the COVID-19 recombinant protein vaccine market.
Similarly, in April 2022, Albumedix Ltd., a leading recombinant protein manufacturer, expanded its existing collaboration with Valneva. This follows the MHRA's recent approval of Valneva's inactivated COVID-19 vaccine containing albumin (VLA 2001), for which Valneva entered into a supply agreement with the European Commission in November 2021 to provide up to 60 million doses over two years. In addition, Valneva reported an advance purchase agreement with the Kingdom of Bahrain in December 2021 for the supply of one million doses. A crucial ingredient in VLA 2001, Albumedix Recombumin, is employed in both the vaccine's manufacture and final formulation. Thus, such developments are fueling the growth of the studied segment.
So, the growth of the market in this segment is likely to be driven by the rise of chronic diseases like diabetes and changes among the major recombinant protein companies.
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North America is expected to lead the recombinant protein market, owing to the increasing expenditure on research, coupled with the presence of healthcare infrastructure and several major recombinant protein companies. The chronic diseases that are on the rise across the region are creating a huge demand for recombinant protein therapies, as recombinant proteins are among the proven solutions for treating such diseases.
Furthermore, novel research for the treatment of various neurodegenerative diseases such as Alzheimer's disease and dementia is also propelling the growth of the studied market. Researchers in Alzheimer's disease require a large amount of time and resources have gone toward a protein called amyloid. Many in the Alzheimer's research community believe targeting amyloid is the key to treating the underlying disease, which is expected to rise the demand for amyloid-based therapies, impacting the protein biological research reagents market.
The increasing number of clinical trial studies in the country is driving the demand for the studied market. For instance, in 2022, Clinicaltrials.gov reported that around 15,316 clinical trials are currently registered in the United States involving biopharmaceuticals in the year 2022. This increasing number of clinical trials studied in the country is anticipated to drive the recombinant protein research reagents market growth in the country.
Additionally, the rising prevalence of chronic diseases among the Mexican population is also expected to drive the growth of the market. For instance, IDF published in December 2021, an estimated 14 million adults in Mexico were living with diabetes. Such a prevalence of diabetes is expected to rise the demand for recombinant proteins, thereby contributing to the growth of the therapeutic protein market over the forecast period.
Thus, owing to the increasing expenditure on research, coupled with the presence of healthcare infrastructure and several major market players and the high prevalence of chronic diseases, the protein production service market in the North American region is expected to project significant growth over the forecast period.
